Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Halofantrine Hydrochloride

FDA-approved product (tablet, oral), marketed as Halfan.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Halofantrine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other antimalarials
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BX01

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Halofantrine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Halofantrine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Remifentanil Anesthesia and Postoperative BIS in Cardiac Surgery

    NCT02400879 · start 2015-10

    Registered record
    Registry ID
    NCT02400879
    Conditions
    Cardiovascular Disease
    Interventions
    Remifentanil; sevoflurane and sufentanil
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-10
    Completion
    2016-10
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Disease
    InterventionRemifentanil; sevoflurane and sufentanil
    PhaseNot applicable
    Registry statusCompleted

  • Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .

    NCT02003703 · start 2015-05

    Registered record
    Registry ID
    NCT02003703
    Conditions
    Hepatitis B; HIV
    Interventions
    Recombinant Hepatitis B Virus Vaccine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-05
    Completion
    2018-12
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B; HIV
    InterventionRecombinant Hepatitis B Virus Vaccine
    PhasePhase 3
    Registry statusCompleted

  • Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia

    NCT02069392 · start 2015-01

    Registered record
    Registry ID
    NCT02069392
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    Cognitive remediation training; Nicotine polacrilex lozenge
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-01
    Completion
    2017-06
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionCognitive remediation training; Nicotine polacrilex lozenge
    PhaseNot applicable
    Registry statusCompleted

  • An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa

    NCT02207816 · start 2014-09-18

    Registered record
    Registry ID
    NCT02207816
    Conditions
    Malaria
    Interventions
    Blood sampling; Malaria Vaccine 257049 (MALARIA-055 PRI); Meningococcal C Conjugate Vaccine (MALARIA-055 PRI); Cell-culture rabies vaccine (MALARIA-055 PRI); TritanrixHepB/Hib (MALARIA-055 PRI); Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-09-18
    Completion
    2017-01-31
    Enrolment
    3,084

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionBlood sampling; Malaria Vaccine 257049 (MALARIA-055 PRI); Meningococcal C Conjugate Vaccine (MALARIA-055 PRI); Cell-culture rabies vaccine (MALARIA-055 PRI) +2 more
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Interaction Between BCG And MenC Immunisation: BAM

    NCT02002156 · start 2014-06-20

    Registered record
    Registry ID
    NCT02002156
    Conditions
    BCG Infection; Reaction - Vaccine; Immune Response
    Interventions
    BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®; BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®; NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-06-20
    Completion
    2018-06-27
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBCG Infection; Reaction - Vaccine; Immune Response
    InterventionBCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®; BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®; NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
    PhasePhase 4
    Registry statusCompleted

  • Atazanavir/r + Lamivudine Dual Therapy

    NCT01599364 · start 2014-04

    Registered record
    Registry ID
    NCT01599364
    Conditions
    Human Immunodeficiency Virus
    Interventions
    Atazanavir, ritonavir, lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-04
    Completion
    2018-02-23
    Enrolment
    266

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    InterventionAtazanavir, ritonavir, lamivudine
    PhasePhase 4
    Registry statusCompleted

  • Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication

    NCT01894269 · start 2013-07

    Registered record
    Registry ID
    NCT01894269
    Conditions
    Hepatocellular Carcinoma
    Interventions
    Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-07
    Completion
    2016-07
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma
    InterventionLamivudine 100mg once daily; or Entecavir 0.5mg once daily.
    PhasePhase 4
    Registry statusUnknown

  • Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old

    NCT01730378 · start 2012-12-05

    Registered record
    Registry ID
    NCT01730378
    Conditions
    Influenza
    Interventions
    Prepandrix™; Fluarix™
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-12-05
    Completion
    2013-12-17
    Enrolment
    131

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfluenza
    InterventionPrepandrix™; Fluarix™
    PhasePhase 4
    Registry statusCompleted

  • Understanding the Immune Response to Two Different Meningitis Vaccines

    NCT01593514 · start 2012-12

    Registered record
    Registry ID
    NCT01593514
    Conditions
    Meningitis; Meningococcal Disease; Septicaemia
    Interventions
    MenACWY-CRM conjugate vaccine (Menveo, Novartis); MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis); MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis); 1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis); Polysaccharide (subcutaneously)-conjugate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-12
    Completion
    2013-04
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeningitis; Meningococcal Disease; Septicaemia
    InterventionMenACWY-CRM conjugate vaccine (Menveo, Novartis); MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis); MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis); 1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis) +1 more
    PhasePhase 4
    Registry statusCompleted

  • Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis

    NCT02015169 · start 2012-07-09

    Registered record
    Registry ID
    NCT02015169
    Conditions
    HER2-positive Gastric Cancer Patients With Liver Metastasis
    Interventions
    Lapatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-07-09
    Completion
    2017-11-17
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-positive Gastric Cancer Patients With Liver Metastasis
    InterventionLapatinib
    PhasePhase 2
    Registry statusCompleted

  • The Impact of Cigarette Smoking on Periodontal Therapy

    NCT05120206 · start 2012-04-01

    Registered record
    Registry ID
    NCT05120206
    Conditions
    Periodontitis; Cigarette Smoking
    Interventions
    Non-surgical periodontal therapy: motivation and instruction in oral hygiene, debridement using handinstrumentation (Hu-Firedy,Chicago, IL, USA; and American Eagle Instruments,Missoula, MT,USA).
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-04-01
    Completion
    2015-03-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeriodontitis; Cigarette Smoking
    InterventionNon-surgical periodontal therapy: motivation and instruction in oral hygiene, debridement using handinstrumentation (Hu-Firedy,Chicago, IL, USA; and American Eagle Instruments,Missoula, MT,USA).
    PhaseNot applicable
    Registry statusCompleted

  • Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)

    NCT01345240 · start 2011-11-17

    Registered record
    Registry ID
    NCT01345240
    Conditions
    Malaria; Malaria Vaccines
    Interventions
    GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049; Engerix-B™ vaccine; Infanrix/Hib™ vaccine; Polio Sabin™ vaccine; Rotarix™ vaccine; Synflorix™ vaccine; Measles vaccine; Yellow fever vaccine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-11-17
    Completion
    2017-02-09
    Enrolment
    705

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Malaria Vaccines
    InterventionGlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049; Engerix-B™ vaccine; Infanrix/Hib™ vaccine; Polio Sabin™ vaccine +4 more
    PhasePhase 3
    Registry statusCompleted

  • Comparison of Conservative and Aggressive Smoking Cessation Treatment Strategies in a Vascular Surgery Office Practice

    NCT01850589 · start 2011-03

    Registered record
    Registry ID
    NCT01850589
    Conditions
    Smoking Cessation
    Interventions
    Aggressive Therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2011-03
    Completion
    2013-01
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmoking Cessation
    InterventionAggressive Therapy
    PhaseNot applicable
    Registry statusTerminated

  • Sevoflurane Versus Intravenous Anaesthetic Agents in Morbid Obese Patients

    NCT01279499 · start 2010-04

    Registered record
    Registry ID
    NCT01279499
    Conditions
    Morbid Obesity
    Interventions
    Sevoflurane; Sevoflurane; Propofol- Remifentanyl; Propofol, Remifentanyl
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2010-04
    Completion
    2011-07
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMorbid Obesity
    InterventionSevoflurane; Sevoflurane; Propofol- Remifentanyl; Propofol, Remifentanyl
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Effect of HPV Vaccination on Women Aged 25 Years

    NCT02296255 · start 2010-04

    Registered record
    Registry ID
    NCT02296255
    Conditions
    Cervical Cancer
    Interventions
    Cervarix®, GlaxoSmithKline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-04
    Completion
    2013-07
    Enrolment
    832

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCervical Cancer
    InterventionCervarix®, GlaxoSmithKline
    PhasePhase 4
    Registry statusCompleted